Integrating Cost into Treatment

Alexander Bastian

Video Categories: Value

According to Alexander Bastian, it’s very difficult to determine how to integrate cost into the equation of cancer care. He explains that cost should be considered early on and uses Dr. Zafar’s term of financial toxicity, meaning the burden of cost can be as bad or worse than a physical side effect.
November 10, 2012

PMO Interview with the Innovator Series: Volume 1

Deborah Dunsire, MD, President and CEO of Millennium: The Takeda Oncology Company, and Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation, discuss the issues and vision in improving personalized medicine strategies for patients with multiple myeloma.Deborah Dunsire, MD, is the former President and CEO of Millennium Pharmaceuticals, [ Read More ]

January 16, 2019

Overcoming Challenges to Molecular Biomarker Testing

Drs. Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges in biomarker testing—tissue stewardship and complexity of biomarker tests and results—and ways to overcome these challenges—improved communication among all members of the cancer care team and simplification of biomarker test results to focus on actionable biomarkers.